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Preclinical atherosclerosis represents a crucial period associated with several pathophysiological reactions in the vascular wall.
Failure to diagnose preclinical atherosclerosis at this stage misses a major opportunity to prevent the long-term consequences
of this disease. Surrogate biological and structural vascular markers are available to determine the presence and the extension
of preclinical vascular injury in the general population. Examples of surrogate markers are carotid intima media thickness and
biomarkersincludinghigh-sensitivityC-reactiveprotein,celladhesionmoleculesandmatrixmetalloproteinases,andleukotrienes.
Recently, leukotrienes have been implicated as mediators, biomarkers, and possible therapeutic targets in the context of subclinical
atherosclerosis. The aim of this short paper is to focus on the relation between preclinical atherosclerosis and leukotrienes, with
particular attention to the recent development on the use of leukotriene modiﬁers in the treatment of atherosclerosis.
1.Introduction
Atherosclerosis, a progressive disease of large arteries with
a long asymptomatic phase, accounts for much of the
global epidemic of cardiovascular disease (CVD). During
the past decades, the concept of atherosclerosis has become
reﬁned with a focus on the inﬂammatory nature of the
atherosclerotic lesion [1].
Inﬂammation in atherosclerosis involves alteration of the
endothelial monolayer, which in the normal state resist pro-
longed contact with leukocytes. Risk factors such as elevated
levels of low-density lipoprotein cholesterol (LDL-C) lead to
endothelial changes [2]. The altered endothelium expresses a
series of adhesion molecules, such as vascular cell adhesion
molecule1 (VCAM-1) and P-selectin, which participate in
the initiation of atherosclerosis [3]. A number of chemoat-
tractants in addition drive the migration of adhered leuko-
cytesintothearterialintimawheretheatheroscleroticlesions
form. This migration result from the action of chemoattrac-
tants, such as monocyte chemoattractant protein 1 (MCP-1)
and leukotriene B4. Atherosclerotic disease progression can
lead eventually to acute cardiovascular events, such as acute
myocardial infarction (AMI), unstable angina (UA) pectoris,
sudden cardiac death, or stroke [4]. While the disease is still
inasubclinicalstage,however,thepresenceofatherosclerosis
can be identiﬁed by several methods, including coronary
angiography,intravascularultrasonography(IVUS),B-mode
ultrasonography, computed tomography (CT) scan, and
magnetic resonance imaging (MRI). In addition, vascular
biomarkers such as high-sensitivity C-reactive protein (hs-
CRP) and cell adhesion molecules have proven to be useful
to predict subclinical atherosclerosis. Recently, leukotrienes
(LTs) have been implicated as mediators, biomarkers, and
possible therapeutic targets in the context of subclinical
atherosclerosis.
2. LTs: Deﬁnition, Synthesis, and Function
LTs are arachidonic acid (AA) derived lipid mediators of
inﬂammation. The initial step in the formation of LTs is cat-
alyzedby5-lipoxygenase(5-LOX)inconjunctionwithitsﬁve
lipoxygenase activating protein (FLAP) [5, 6]. Subsequently,
LTC4 synthase leads to the formation of the family of cys-
teinylleukotrienes(CysLTs)includingleukotrieneC4 (LTC4),
leukotriene D4 (LTD4), and leukotriene E4 (LTE4), whereas
the noncysteine-containing dihydroxyleukotriene B4 (LTB4)
is formed through the action of the enzyme LTA4 hydrolase2 The Scientiﬁc World Journal
[6]. LTs are mainly produced by macrophages inﬁltrating
atherosclerotic lesions and act in an autocrine/paracrine
manner within the vascular wall. For example, LTB4 is a
potent chemoattractant for monocytes, neutrophil granulo-
cytes, and T lymphocytes, that promotes leukocyte adhesion
to vascular endothelium, augments vascular permeability,
and promotes vascular smooth cells (VSMCs) proliferation
and migration [7, 8]. The two receptors for LTB4 are
termed BLT1 and BLT2. The BLT1 receptor is the high-
aﬃnity receptor speciﬁc for LTB4 expressed in leukocytes,
vascularsmoothmusclecells,andendothelialcellsandmedi-
ates chemotaxis [9]; BLT2 is a pharmacologically distinct
receptor ubiquitously expressed and displays low aﬃnity
for LTB4 and also binds other agonists [10]. For example,
the thromboxane synthase metabolite 12-L-hydroxy-5,8,10-
heptadecatrienoic acid (12-HHT) has been identiﬁed as a
more potent ligand for BLT2 than LTB4, although the speciﬁc
role of 12-HHT activation of leukotriene receptors in CVD
has not been extensively explored [11].
CysLTs (LTC4,L T D 4,a n dL T E 4) are potent vasoconstric-
torsandalsoenhancevascularpermeability[12].Inaddition,
in vivo studies have shown that CysLTs, reduce coronary
blood ﬂow, decrease myocardial contractility, and regulate
blood pressure [13]. CysLTs also stimulate proliferation of
arterial smooth muscle cells and promote P-selectin surface
expression, von Willebrand factor secretion, and platelet-
activating factor (PAF) synthesis in cultured endothelial cells
(EC) [14]. CysLTs exert their biological eﬀects by activating
speciﬁc receptors termed CysLT1 and CysLT2, of which the
CysLT1 receptor is blocked by the antileukotrienes used
clinically in the treatment of asthma [10].
3.Endothelial Dysfunction:APreclinical
Atherosclerosis Phase
Endothelial injury may be one starting point for atheroscle-
rosis. Such injury can result from a variety of factors, includ-
ing increased local shear forces from hypertension, elevated
plasma concentrations of LDL-C, chemical toxins in for
examplecigarettesmoke,anddiabetesmellitus.Thesefactors
decrease (EC) production of nitric oxide (NO), thereby
impairing vasodilatory capacity, normal barrier, and protec-
tive functions of the vascular endothelium. Dysfunctional
EC in addition upregulate, a number of adhesion molecules,
which promote the binding of circulating monocytes to
vascular EC [15]. Whereas EC in nonatherosclerotic arteries
are devoid of BLT receptors, the endothelium lining human
carotid atherosclerotic lesions have been demonstrated to
be positive for the BLT1 receptor [16]. In line with these
ﬁndings, human umbilical vein endothelial cells (HUVECs)
exhibit BLT1 upregulation after stimulation with the proin-
ﬂammatory cytokines LPS and IL-1β in vitro [17]. In
addition, in vitro studies have demonstrated a LTB4-induced
release of vasoactive factors via BLT receptor activation [18,
19]. These reports provide evidence for a role of LTB4 in
regulating endothelial function.
The CysLT2 receptor appears to be the dominating CysLT
receptor in normal EC [20], but endothelial CysLT1 receptor
expression can be induced after prolonged exposure to IL-
1β [21]. Furthermore, studies of human brain tissue have
revealed CysLT1 receptor immunostaining in microvascular
EC [22]. Studies in isolated vessels have associated CysLT1
receptor signaling with the release of contractile factors,
whereas the CysLT2 receptor appears preferentially cou-
pled to the release of NO [23]. Furthermore, LTC4 and
LTD4 upregulate endothelial P-selectin expression [24]a n d
increase the transcription of the CXC chemokines MIP2-α
[25] and IL-8 [26].
4.Immunoactivation:APivotalStepin
Atherosclerosis Progression
The dysfunctional endothelium will hence promote the
recruitment of immune cells. Once attached, monocytes
will be exposed to several chemokines that promote the
transmigration of bound monocytes into the subendothelial
space, and to colony stimulating factors, that promotes the
diﬀerentiation of monocytes into macrophages. In addi-
tion to the stimulation of endothelial adhesion molecules
discussed above, the direct chemotactic activity of LTB4
may also participate in monocyte/macrophage accumulation
during atherogenesis.
Macrophages expressing scavenger receptors (SRA, CD-
36) will bind and promote the internalization of oxidized
LDL (LDLox)a n dab r o a dr a n g eo fo t h e rp a r t i c l e sa n d
cell fragments [15]. As the macrophages progressively accu-
mulate more and more cholesterol, cytosolic lipid droplets
form, and the macrophage become a lipid-laden foam cell.
Although the exact role of LTs in oxidized LDL uptake
remains to be established, the enhanced CD-36 expression
andincreaseduptakeofLDLox inducedby4-hydroxynonenal
are blunted when 5-LO activity is inhibited by a pharma-
cological inhibitor, and in macrophages derived from 5-
LO-deﬁcient mice [27]. Furthermore, LDLox upregulates
FLAP expression in monocytic cell lines [28], suggesting
also an enhancing function of LDLox on leukotriene-driven
inﬂammation in atherosclerosis. In addition to monocytes,
T-lymphocytes inﬁltrate the developing lesion site from both
the intimal and adventitial aspects of the vessel wall [29, 30].
LTB4 is a potent chemoattractant for T-lymphocytes and
may also be a key mediator in a lymphocyte-monocyte
cross-talkenhancinginﬂammatorycircuitsinatherosclerosis
[31]. In addition, LTB4 stimulates the release of matrix
metalloproteinases (MMPs) from T-lymphocytes in vitro
[32] .T h eM M Pf a m i l yo fe n z y m e si si n v o l v e di na r t e r i a lw a l l
extracellular matrix degradation and remodeling [33]. In
additiontostimulatingT-lymphocyteMMPs,LTsalsoinduce
MMP release from neutrophil granulocytes [34], monocytes
[35], and vascular smooth muscle cells [36, 37].
5. Biomarkers of SubclinicalAtherosclerosis
Dysfunction of the endothelium may be considered as
an early and potentially reversible step in the process of
atherogenesis, and numerous methods have been developed
to assess endothelial status and large artery stiﬀness [38].The Scientiﬁc World Journal 3
Severalbiochemicalmarkershavebeenidentiﬁed,whichcor-
relate with coronary artery disease (CAD) and conventional
CVD risk factors [39]. Such biomarkers include, LDLox, hs-
CRP, endothelial progenitor cells (EPC), prothrombotic fac-
torssuchasvonWillebrandfactor(VWF),andinﬂammatory
markers including tumor necrosis factor-α (TNF-α), IL-6,
and intracellular adhesion molecule-1 (ICAM-1) [40, 41], as
well as diﬀerent members of the MMP family [33].
6. LTs and SubclinicalAtherosclerosis:
GeneticEvidence
The ﬁrst suggestion for the involvement of the LTs pathway
in subclinical atherosclerosis was provided by Dwyer and
coworkers, reporting an association of the number of
Sp1/Egr1 motifs within the 5-LO promoter sequence with an
increased carotid intima-media thickness [42]. In the latter
study, carriers of the variant genotypes in addition exhibited
2-fold higher levels of hs-CRP. Genetic variations in other
constituents of the LTs pathway have also been demonstrated
to correlate with measures of subclinical atherosclerosis.
For example, a SNP within the LTC4 synthase promoter
correlatedwithcarotidintima-mediathicknessandcoronary
calcium [43]. Finally, the genetic association of the LTs
pathway with atherosclerosis is also supported by studies of
CVD outcomes, in which variations in the genes encoding
FLAP, LTC4 synthase, and LTA4 hydrolase [44]h a v eb e e n
associated with a higher prevalence of MI and/or stroke.
7. LTs and Atherosclerosis:
ExperimentalEvidence
Targeting the 5-LO enzyme in animal models of atheroscle-
rosis have generated contradictory results [45, 46]. However,
pharmacological inhibition of FLAP in diﬀerent atheroscle-
rosis prone mice has shown reduced lesion size [31, 47, 48].
LTB4 is one of the most potent chemoattractants formed
within the atherosclerotic lesion, and several leukocyte
subpopulations with importance for atherosclerosis devel-
opment have been shown to be activated by LTB4 [49]. In
human atherosclerotic lesions, macrophages stain positive
forbothBLTreceptorsubtypes[16],andinvitrostudieshave
supported a role for both the high-aﬃnity BLT1 receptor and
the low-aﬃnity BLT2 receptor in macrophage recruitment to
atherosclerotic lesions [16, 34]. Furthermore, BLT receptor
expression on T-lymphocytes may play a key role in the
immunological reactions within the atherosclerotic lesion
[31]. In addition to macrophages and T-lymphocytes, also
granulocytes express BLT receptors [49] and, although
incompletely explored in atherosclerosis, LTB4 was recently
demonstrated as a key mediator of neutrophil chemotaxis
and activation in human aortic abdominal aneurysms [34].
In addition to leukocyte activation, LTB4 also induces
eﬀects on structural components of the vascular wall [16, 36,
50, 51]. In addition to endothelium-dependent vasomotor
responses discussed above, LTB4 also induces contractions
of some vascular segments lacking a functional endothelium
[52], and BLT receptor expression was subsequently demon-
s t r a t e do nV S M C[ 16, 53]. Furthermore, experimental mod-
elstargetingtheBLT1 receptorhaveindicatedtheimportance
of LTB4-induced VSMC migration and proliferation in
the development of atherosclerosis [16, 53]. Finally, BLT
receptor antagonism reduces the intimal hyperplasia in
response to balloon angioplasty with stent implantation
in hypercholesterolemic rabbits [36], suggesting a potential
use of antileukotrienes in the prevention of restenosis
following coronary percutaneous interventions. Likewise,
either pharmacological [54, 55]o rg e n e t i c[ 55, 56] targeting
of the BLT receptor reduces atherosclerotic lesion size in
hyperlipidemic mice.
CysLTs induce contraction of atherosclerotic human
coronary arteries [57]. Recently, the CysLT pathway was
associated with aortic stenosis, a vascular inﬂammation
which shares several characteristics with atherosclerosis [58].
In this context, LTC4 stimulation of valvular myoﬁbroblasts
increased reactive oxygen species production and induced
calciﬁcation. In addition, the local expression levels of 5LO
correlated with the severity of valvular disease, suggesting
that the role of the leukotriene pathway in CVD may extend
beyond atherosclerosis.
Pharmacological targeting of the CysLT1 receptor retards
atheroscleroticlesiongrowthinhyperlipidemicmice[59,60]
and reduces the intimal hyperplasia in response to vascular
injury [61].
8. LTs as Biomarkers of Atherosclerosis and
CVRisk
Ex vivo incubations of human atherosclerotic lesions have
shown an increased release of both CysLTs [62]a n dL T B 4
[63] compared with healthy human vessels. Brezinski et
al. [64] detected an increased local LTs production during
coronary interventions, and a systemic increase in LTB4
formation has been detected through ex vivo stimulation of
leukocytes derived from patients with a history of AMI [65].
The latter approach was recently used in a study of subjects
with obstructive sleep apnea [66], which demonstrated
correlations of LTB4 concentrations with measures of carotid
artery remodelling. Patients with obstructive sleep apnoea
in addition exhibit urinary excretion of LTE4,w h i c hi s
associated with the severity of sleep apnoea and obesity [67].
Since both sleep apnoea and obesity are established CVD
risk factors, the latter ﬁndings warrant further investigation
of the potential of LTs as biomarkers of atherosclerosis and
CVD risk. Finally, oral concentrations of LTs may represent
another interesting approach for the evaluation of LTs as
CVD biomarkers [68]. For example, subjects with high
concentrations of CysLTs in gingival crevicular ﬂuid have an
increased carotid artery wall thickness, regardless of their
dental status [69].
9. LT Modiﬁers and Atherosclerosis:
The ClinicalExperience
Inﬂammation plays an important role in atherosclerosis
process. In particular, many enzymes associated with the4 The Scientiﬁc World Journal
5LO pathway are abundantly expressed in arterial walls of
patients aﬄicted with various lesion stages of atheroscle-
rosis of the aorta and of coronary arteries [41]. In a
randomized, placebo-controlled trial, Hakonarson et al. [70]
demonstrated that an inhibitor of FLAP (DG-031) led to
signiﬁcant and dose-dependent suppression of plasmatic
biomarkers that are associated with increased risk of AMI
events. The authors randomized 191 patients, who carry at-
risk variants in the arachidonate 5-lipoxygenase-activating
protein (ALOX5AP) gene (87%) or in the leukotriene A4
hydrolase gene (13%), to receive 250mg/d of DG-031,
500mg/d of DG-031, 750mg/d of DG-031, or placebo for
4 weeks. In patients with speciﬁc at-risk variants of 2 genes
in the leukotriene pathway, DG-031 led to signiﬁcant and
dose-dependent suppression of hs-CRP that is associated
with increased risk of AMI events. Even Allayee et al.
[71] provided evidence that montelukast and low-dose
theophylline decrease certain inﬂammatory and lipid CVD
risk factors. In this study, the authors randomized 133
patients with moderate-to-severe asthma to receive either
montelukast (10mg/d), theophylline (300mg/d), or placebo
for 6 months. Asthmatic patients receiving montelukast and,
to some extent, low-dose theophylline have lower levels of
CVD-associated inﬂammatory biomarkers (hs-CRP, IL-6)
and lipid levels.
In acute coronary syndrome (ACS), a potent 5LO
inhibitor (VIA-2291) reduces leukotriene production as
demonstrated by Tardif et al. [72] in a double blind trial with
placebo. In this study, 191 patients were randomly assigned
3 weeks after an ACS to receive 25, 50, or 100mg VIA-
2291 or placebo daily for 12 weeks. A signiﬁcant reduction
of urine leukotriene LTE4 was obtained in all dose groups
with the absence of serious adverse events. In this study, a
subsetofpatients(n = 60)underwenta64-slicecoronaryCT
examination at baseline continued on study medication for a
total of 24 weeks and underwent a repeat scan. A signiﬁcant
reduction in noncalciﬁed plaque volume at 24 weeks versus
placebo was observed in VIA-2291—treated groups in the 34
of these 60 patients in whom this end point was analyzable.
Inaregistry-basednation-wideSwedishcohortofalmost
7 million subjects followed for 3.5 years, montelukast use
was associated with a borderline signiﬁcant protective eﬀect
on recurrent stroke [73]. Based on signiﬁcant interactions, a
subgroup analysis revealed that montelukast use was associ-
ated with a signiﬁcantly reduced risk of recurrent stroke in
subjects not receiving angiotensin-modifying drugs. In the
same study, a stratiﬁed analysis revealed that montelukast
use signiﬁcantly reduced the risk of recurrent myocardial
infarction in males [73]. These results provide a ﬁrst
indication for beneﬁcial eﬀects of the CysLT1 receptor
antagonistmontelukastinthesecondarypreventionofstroke
and myocardial infarction.
10. Conclusions
The inﬂammatory process of atherosclerosis is associated
with several pathophysiological reactions characterized by
theproductionofLTs,whichinduceproinﬂammatorysignal-
ing through activation of speciﬁc BLT and CysLT receptors.
CysLTs and LTB4 exertarangeoftheproinﬂammatoryeﬀects
and have proved to be important mediators in inﬂammatory
conditionssuchaspreclinicalatherosclerosis.Forthisreason,
leukotriene synthesis inhibitors and leukotriene receptor
antagonists have been suggested to induce beneﬁcial eﬀects
at preclinical stages of the atherosclerotic process.
Further experimental and clinical studies are needed
to determine the potential therapeutic strategies targeting
the LT pathway in CVD for to increase a potential use of
these drugs in cardiovascular and cerebrovascular diseases
[74, 75]. The exact role of LTRAs in disease management
is still evolving. Large-scale, controlled trials are needed to
determine the eﬀectiveness and the safety deriving from the
use of LTRAs in CVD.
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